LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTSPRNewsWire • 10/02/25
2 High-Yield Dividend Growth Stocks to Buy in October and Hold for a Decade or LongerThe Motley Fool • 10/02/25
Goldman Sachs Sees 4 Rate Cuts by Next Summer: 5 High-Yield Dividend Winners24/7 Wall Street • 09/26/25
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBSPRNewsWire • 09/26/25
Amgen Inc. (AMGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/09/25
Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic DermatitisGlobeNewsWire • 09/09/25
If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have TodayThe Motley Fool • 09/09/25
AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITISPRNewsWire • 09/09/25
Amgen Inc. (AMGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeeking Alpha • 09/03/25